SEARCH

SEARCH BY CITATION

Keywords:

  • intermediate-risk neuroblastoma;
  • neuroblastoma;
  • refractory disease

Abstract

Patients <12 months with favorable biology, metastatic neuroblastoma have >90% overall survival following treatment with chemotherapy and surgery. We report two infants with favorable biology, stage 4 neuroblastoma with refractory disease after standard intermediate-risk chemotherapy and additional retrieval chemotherapy. One patient was treated with six additional cycles of isotretinoin and the other observed. Both remain clinically well with persistent disease but no evidence of tumor progression for 28 and 13 months following completion of cytotoxic treatment. Similar to residual tumor in primary sites, refractory metastatic disease may not portend a poor outcome in patients with favorable biology, intermediate-risk neuroblastoma. Pediatr Blood Cancer 2014;61:1104–1106. © 2013 Wiley Periodicals, Inc.